Combination therapy with SGLT2-inhibitors and Tafamidis in transthyretin cardiomyopathy
{{output}}
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with high morbidity and mortality. Tafamidis is the only US Food and Drug Administration-approved disease-modifying therapy. Sodium-gl... ...
